Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
2 min synopsisUK scopeSources checked 8 Sept 2026Clinical review pending
Saved on this device
!
Escalate
New sepsis, organ failure, bleeding or suspected bowel ischaemia in necrotizing pancreatitis needs urgent multidisciplinary assessment. Waiting for a mature wall is conditional on the patient being able to wait safely.
Synopsis
Distinguish sterile pancreatic necrosis from suspected infection, choose appropriate antimicrobial and source-control decisions, and reassess the response within a specialist step-up strategy.
Necrosis may remain sterile; neither its extent nor an isolated fever justifies prophylactic antibiotics.
Suspect infected necrosis from the clinical course, sepsis features and imaging; gas or an appropriate positive culture strengthens the diagnosis.
For suspected infection, give appropriate IV antibiotics and assess source control. Delay intervention while clinically safe; persistent sepsis may need earlier drainage, followed by debridement only if required.
Key red flags
New or worsening organ dysfunction after an initially stabilising course.
Blood in a drain, gastrointestinal bleeding or a falling haemoglobin with circulatory change.
Peritonism, worsening abdominal distension or concern for intestinal ischaemia or perforation.
Bleeding and bowel emergencies
A sudden haemoglobin fall, haemodynamic instability, gastrointestinal bleeding or blood from an existing drain raises concern for vascular erosion or pseudoaneurysm. Peritonism or evidence of bowel ischaemia/perforation is another urgent pathway. These complications can require immediate interventional radiology or surgery; they do not wait for routine collection maturation.
Investigation priorities
01
Contrast-enhanced CT for the new clinical questionFirst step
Define necrosis, collection anatomy and a cause of deterioration.
Management branches
Worked caseDeterioration despite active antibiotics
A constructed example shows why drainage can precede four weeks.
A 56-year-old woman develops fever and new circulatory instability on day 19 after necrotizing pancreatitis. CT shows gas in a partially encapsulated collection adjacent to the stomach, with no previous drain or visible bowel fistula. The pancreatic team treats suspected infected necrosis, obtains cultures and starts an appropriate intravenous antibiotic; she has no beta-lactam allergy and renal function is preserved.
Despite initial support and Sandoz piperacillin/tazobactam 4 g/0.5 g intravenously every eight hours over 30 minutes, sepsis persists. At multidisciplinary review on day 21, imaging shows an accessible partially formed wall. The team undertakes EUS-guided drainage rather than waiting until day 28 or proceeding directly to open necrosectomy. In the following 48 hours she becomes afebrile, circulatory support is withdrawn and intake improves, supporting continuation of the step-up plan without necrosectomy.
Key medicines
Sandoz piperacillin/tazobactam 4 g/0.5 g infusionA UK hospital example for established infected pancreatic necrosis in an appropriate adult is 4 g piperacillin plus 0.5 g tazobactam intravenously every eight hours, infused over 30 minutes. The UHB example uses five days depending on clinical response, with a culture and clinical review at 48–72 hours; the pancreatic/microbiology team determines continuation or stopping from infection control and drainage response. For this Sandoz product, reconstitute the vial with 20 mL of a compatible solvent, such as 0.9% sodium chloride, and further dilute to an appropriate final volume of 50–150 mL, for example 100 mL. At creatinine clearance 20–40 mL/min, the suggested maximum is 4.5 g every eight hours; below 20 mL/min it is 4.5 g every 12 hours. Haemodialysis requires an additional 2.25 g after each dialysis period.Do not give with penicillin/active-substance/excipient hypersensitivity or a previous acute severe reaction to another beta-lactam; obtain a suitable alternative promptly with microbiology. No hepatic dose adjustment is specified, but renal function determines adjustment, including in older adults. The product is not recommended for ESBL-producing E. coli or K. pneumoniae bacteraemia. Review cultures, kidney function, potassium, blood counts and bleeding; concurrent vancomycin increases kidney-injury risk, methotrexate clearance can fall and anticoagulant effects require monitoring. Stop and assess severe hypersensitivity, progressive severe rash, persistent severe diarrhoea, rhabdomyolysis or suspected drug-related immune activation; established HLH requires discontinuation. Each vial contains 217 mg sodium. Prepare aseptically, use promptly and administer separately from other drugs unless compatibility is established; this formulation is incompatible with lactated Ringer’s/Hartmann’s. Pregnancy or breastfeeding use requires a clear benefit–risk decision. Review the course daily and do not prolong treatment merely for a residual sterile cavity.
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 8 Sept 2026; clinical approval remains outstanding.